Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.76 |
| ▸ | PPARA | Q07869 | 16/20 | 0.76 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27546489 | 0.94 | PPARG (0.67) | PPARGPPARALTA4HPPARDLMNA | |
| SCHEMBL5389840 | 0.93 | PPARG (0.65) | PPARGPPARALTA4HPPARD | |
| SCHEMBL5355177 | 0.89 | LTA4H (0.67) | PPARGPPARALTA4HPPARD | |
| SCHEMBL29163290 | 0.89 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL6716134 | 0.88 | PPARA (0.74) | PPARGPPARALTA4HPPARDLMNA | |
| SCHEMBL3250931 | 0.86 | PPARG (0.62) | PPARGPPARALTA4HPPARDLMNA | |
| SCHEMBL6713386 | 0.86 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL5377352 | 0.86 | TSHR (0.63) | PPARGPPARA | |
| SCHEMBL7191581 | 0.86 | PPARA (0.73) | PPARGPPARALTA4HPPARDLMNA | |
| SCHEMBL5364064 | 0.86 | PPARA (0.73) | PPARGPPARALTA4HPPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| CN-1312795-A | Novel 3-arylpropionic acid derivatives and analogs thereof | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-09-12 | — | — | CN | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885LTA4H 2565/4885 |
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885LTA4H 3298/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885LTA4H 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.